-
-
-
-
-
-
-
Jaguar Health Reports Second Quarter 2026 Financials
-
-
-
-
-
-
-
Jaguar Health (JAGX) files for 5.52M share offering by selling stockholders
-
-
-
-
-
-
-
Jaguar Health explores strategic alternatives amid rare disease NDA push
-
-
-
-
-
-
-
Jaguar Health reports stockholder approval of all annual meeting proposals
-
-
-
-
-
-
-
Jaguar Health Reports First Quarter 2026 Financials
-
-
-
-
-
-
-
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
-
-
-
-
-
-
-
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
-
459,742 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

